Reviva Pharmaceuticals Q3 net loss narrows
Reviva Pharmaceuticals reported a Q3 net loss of $4 million, an improvement from last year's $8.4 million loss. The company plans a pre-NDA meeting with the FDA for brilaroxazine in Q4 2025 and received a European patent for brilaroxazine in pulmonary fibrosis. They raised $9 million through a public equity offering. Analysts rate the stock as a "buy," with a median 12-month price target of $3.00, significantly above the current price.
)
Overview
- Reviva reports Q3 net loss of $4 mln, improved from $8.4 mln loss last year
- Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025
- European patent granted for brilaroxazine in pulmonary fibrosis
Outlook
- Company plans pre-NDA meeting with FDA for brilaroxazine in Q4 2025
Result Drivers
- EQUITY OFFERING - Raised $9 mln through public equity offering to support ongoing research and development
Key Details
Metric Beat/Mis Actual Consensu
s s
Estimate
Q3 EPS -$0.06
Q3 Net -$4 mln
Income
Analyst Coverage
- The current average analyst rating on the shares is “buy” and the breakdown of recommendations is 7 “strong buy” or “buy”, no “hold” and no “sell” or “strong sell”
- The average consensus recommendation for the biotechnology & medical research peer group is “buy”
- Wall Street’s median 12-month price target for Reviva Pharmaceuticals Holdings Inc is $3.00, about 80.7% above its November 12 closing price of $0.58
Press Release: For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact . (This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
